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14. ABSTRACT 1 INTRODUCTION In imny instances, operational performance may be increased if operators were able to accomplish sleep during brief (<6 hrs) daytime break periods. Operational examples include individuals rotating schedules (i.e., preparing for an initial ni^t shift), night work, and sustained work environments (i.e., military operations). It is difficult if not impossible to accomplish daytime sleep in many circumstances. This may be due to environmental factors (e.g., noise, light), subjective factors (e.g., anxiety), or circadian factors (e.g., reduced melatonin production). In these cases an effective short-acting sleep aid may provide a substantial inprovement in the ability to acquire daytime sleep. The aid of choice should have a relatively short half-life and few side effects upon awakening from sleep. In addition, flie sleep-aid should have minimal side effects when sleepers are awakened unexpectedly and required to return to work. Finally, the sleep-aid of choice should be effective at inducing and maintaining daytime sleep. As detailed in the following paragraphs, zaleplon (marketed in the United States by Wyeth-Ayerst Pharmaceuticals under the name Sonata®) may be a sleep aid that would fulfill these requirements.
Maximum plasma concentrations of zaleplon occur at approximately 1-hr post-dose with a half-life of about 1-hr (Beer, leni, Wu, Clody, Amorusi, Rose, Mant, Gaudreault, Cato, and Stem, 1994) . Zaleplon is commonly administered in 10-mg oral doses, but is also given in 20-mg doses to people more resistant to its effects, for the treatment of insomnia. The most common side effects include: headache, dizziness and somnolence. Outside of somnolence, in short-term clinical studies, the subjective side effects for zaleplon are not significantly different from placebo following a night of sleep (Elie et al.) . Thus, from a pharmacokinetic and synptomatic perspective it appears that zaleplon may be suited for situations where a rest break of at least 4-hours duration is available.
Zaleplon has been ffiown to reduce nighttime sleep latency in adult insomniacs at the 10-mg dose level (Elie, Ruther, Farr, Emilien, & Salinas, 1999) . Hedner, Yaeche, Emilien, Farr, & Salinas (2000) showed an increase in subjective sleep quality and subjective total sleep time for nighttime sleep in elderly insomniacs. This group also found a reduction in subjective sleep latency for both 5 and 10-mg doses. Fiy, Scharf, Mangano, & Fujimori (2000) found zaleplon to be an effective sleep aid (5,10, & 20-mg) vidthout wdthdrawal symptoms in outpatient insomniacs. Walsh, Vogel, Scharf, Erman, William, Schweitzer, Mangano, and Roth (2000) evaluated the h:^notic efficacy of 10-mg zaleplon and found a significant reduction in nighttime sleep latency (subjective and polysomnographic data). Total sleep length was not sigmficantly increased. This 5-week study found no rebound insomnia upon zaleplon termination. In summaiy, there is significant evidence to support the hypnotic efficacy of zaleplon in insomniacs attempting to sleep at night. The question of whether there are benefits to normal rested individuals attempting daytime sleep remains.
Several studies have found little or no difference in performance following a night-time administration of zaleplon (Danjou, Paty, Fruncillo, Worthington, Unruh, Cevallos, & Martion, 1999; Hindmarch, Patat, Stanley, Paty & Rigney, 2001; Troy, Lucid, Unruh, Cevallos, Leister, Martin, Furlan, and Mangano, 2000) . However, several other studies have discerned some negative performance effects (Vermeers, Danjou, & O'Hanlon, 1998; Curran, & Lader, 1993 , Beer et al., 1994 . Only one study to date has fomd significant negative effects beyond three hours post-dose for a single dose of 10-mg zaleplon (Vermeeren et al.) . In previous work (Whitmore, Fischer, Barton, & Storm, 2003) , we explored zaleplon's deleterious effects upon performance following an unanticipated awakening from daytime sleep. This study found conqjlex cognitive performance to be significantly affected up to 3-hrs post dose. However, simpler performance measures (i.e., simple reaction time, grip strength) were unaffected. The short duration of negative performance inpact supports zaleplon usage in environments where only a brief period is available for sleep. Our present study is somewhat different from those described in the preceding paragraphs. This study was designed to examine zaleplon's ability to improve both the quantity and quality of daytime sleep in a
METHODS

Participants
Twelve participants, six males and six females, volunteered to participate in this study. The mean age of the group was 28.1 years (range 19 -43 yrs). The mean weight for males was 78.65 kg. (range 63.50 -89.36 kg) and the mean weight for females was 58.33 kg (range 44.45 -70.31 kg). Based upon a participant demographic survey, participants were normally entrained individuals (i.e., no night-shift workers), who were not heavy caffeine users. Participants were screened medically (blood chemistiy and liver function) prior to their first experimental session. The study required a total of 23 hours of time per individual. Participants were paid for their participation and signed a voluntary consent document prior to participation. Because of facility accommodation limitations, participants were formed into three groups of four participants each. Each group of participants experienced one experimental session per week (10-hours duration) for two successive weeks. In addition a 3-hour training session was conducted the week prior to the first experimental session. The research protocol for this experiment was reviewed by the Brooks Air Force Base Institutional Review Board and approved by the Air Force Surgeon General (#F-BR-2002-0030-H). All funding for this effort came fi-om the Air Force Research Laboratory flirough contract #F41624-97-D-6004.
Design
The study was conducted using a repeated measures design with two within-subject factors: drug (zaleplon or placebo), and trial (six data collection time points; Table 1 ). Each participant experienced both drug conditions. The two experimental sessions were separated by one week. Drug administration was counterbalanced and double-blinded. Participants were asked not to consume alcohol the night before an experimental session, and to drink no more than one caffeinated beverage on the morning of an experimental session. They were told to get a good (normal) night's sleep the night before each session.
Facility and Materials
The study was conducted at the Chronobiology and Sleep Laboratory (CASL) located at Brooks Air Force Base. Each participant was assigned a number under which his or her data was recorded to maintain anonymity. The lab layout consisted of four bedrooms and bathrooms, and one additional room containing equipment for measuring postural sway. Participants completed cognitive tasls at computer workstations within their bedrooms. The workstations were located next to the beds so that participants could sit down at their desks immediately upon waking. Participants completed all cognitive tasks with their bedroom door closed to limit distractions. Audio-visual equipment was used to monitor the testing areas for safety purposes.
The zaleplon doses used in this study were 10-mg Sonata® capsules obtained in an unopened manufacturers bottle. These capsules were individually re-packaged inside a gelatin capsule. Gelatin (Perez, Masline, Ramsey, & Urban, 1987) , was administered at each of the six test trials (see Table 1 ), each test day. The entire ANAM test battery took 13 to 15 minutes to complete. All tests are listed below in the order of presentation. Table 2 shows the individual test start times and durations during the first test block after awakening.
Stanford Sleepiness Scale (SSS) -Participants chose one of seven Likert-scale descriptors, ranging from 1, "Feeling active and vital; alert; wide awake," to 7, "Almost in reverie; sleep onset soon; lost struggle to remain awake." (Hoddes, Zarcone, Smythe, Phillips, & Dement, 1973) Code Substitution Learning Test -This test provided a reference row with pairs of numbers and associated symbols at the top of the screen. During the test, individual stimulus items containing one pair, number and symbol, were presented below the reference row. Participants used the reference row to determine whether or not a number and symbol were associated with each other. A total of 72 items were presented during this test.
Code Substitution Immediate Memory Test -This test presented 18 number and s3nnbol items, without providing the reference row of numbers and symbols. Participants were to recall the Learning Test associations to make their determination.
Simple Reaction Time Test (SRT) -This test required participants to respond as quickly as possible with a mouse click to an asterisk stimulus appearing on the screen. A total of 20 stimuli were presented.
Mathematical Processing Test -This test called for participants to perform addition and subtraction problems by responding to whether or not the answer was greater or less than 5 with the answer never being 5. Each problem consisted of three single-digit numbers and two operands. The test lasted for 3 minutes.
Matching to Sample Test -This test displayed a sample matrix box containing a pattern of red and blue squares. After the sample matrix was presented, it was replaced with two matrix boxes. Participants had to decide which of the two matrix boxes matched the sample stimulus using a left or right mouse click. The test lasted for 3 minutes.
Sjmibolic Logical Reasoning Test -In this test, participants answered whether a single statement accurately described the relational order of two symbols (# and &). The test lasted 3 minutes.
Code Substitution Delayed Memory Test -This test was similar to the Immediate Memory Test, but contained 36 items. Again, participants had to respond to whether the number and symbol stimulus were associated based upon the reference row provided only during the Code Substitution Learning Test.
In general, for these ANAM tests, the following outcome measures were recorded for analysis: accuracy, mean reaction time to correct responses (MRTC), standard deviation of reaction time to correct responses (SDRTC), throughput ((60,000/RTaii) * % Correct), and omissions. The exceptions to this rule were the SSS (a single sleepiness rating from 1 to 7 was recorded), and SRT (only mean reaction time, percent omissions, and standard deviation for reaction time were examined).
Word Memory Test -This test provided an assessment of short-term memory. In this study it was used to test for anterograde amnesia effects. Approximately 30 minutes after awakening, the participants were aurally presented a 15-word list. They wrote down the words on a piece of paper. The word lists were selected from the Williams Word Memory Test (Williams & Williams, 1966) . After a one-minute memorization period, participants handed in their papers. Fifteen minutes later they were asked to recall the list on paper. After an additional three hours, participants were asked once more to recall and write down as much of the list as possible. The number correct was the single outcome measure derived from this test.
Psychomotor Vigilance Task -The PVT required sustained attention and discrete motor responses (Dinges, 1992) . The 8" x4.5" x 2.4" portable, battery-operated device presented a continuous simple reaction time test for 10-minutes. Training required only one ten-minute practice session. The PVT was self-administered at all trials. The outcome measures from this test were mean reciprocal reaction time (MRRT), standard deviation of RRT (SDRRT), and number of lapses. RRT was used here instead of RT because of the nature of the PVT, which tends to exacerbate the usual problems with RT data (e.g. skewness).
Profile of Mood States (POMS) -
This paper-and-pencil survey was used to assess affect (McNair, Loir, & Droppleman, 1971) . The POMS consisted of sixty-five adjectives describing feeling and mood to which the participant responded according to a five-point scale ranging from "Not at all" to "Extremely." There were six subscales derived from the questions: Depression, Tension, Vigor, Fatigue, Anger and Confusion. The POMS was administered at all trials.
Sleep Aid Symptom Questionnaire -To assess sleep aid subjective effects, participants were asked to complete a symptom survey containing 56 items, each scored on a scale ranging from 0-7, where 0 was "none" and 7 was "severe". Participants were to note whether or not they thought that the drug administration caused the symptom and also to what extent they thought the symptom would interfere with daily activities. Of the 56 symptoms, 17 were considered to be relevant to this study, and only those were analyzed. The questionnaire also called for participants to indicate whether or not they thought they received the placebo or Sonata. Participants completed this questionnaire every trial. (Patat & Foulhoux, 1985) . The participants' posture was heels together, feet open at a 30-deg angle, and hands at sides, much like a relaxed version of the military position of attention. One minute of data was collected for both eyes open and eyes closed conditions, at a sampling rate of 10 Hz. The Force Platform Test was completed every trial. An area measurement that accounted for 95% (A95) of the variation in the center of pressure changes was used as the outcome measure.
Polysomnography -Sleep onset and quality during the experiment were assessed with ambulatory electrophysiological equipment. Brain electrical signals were acquired from the 04, C2, A1 and A2 scalp leads of the International 10-20 system (Jasper, 1958) with an EEG Technology ambulatory recorder (model #34-24R8B20, Leveroy, Netherlands) and analyzed with software developed by Stellate Systems (Montreal, Canada). The EEG signal was digitized at 128 samples/sec. EOG signals were also acquired to support sleep scoring by a polysomnographic technologist. In total, ten electrodes were used (3 scalp, 2 mastoid, 2 outer canthi, 2 chin, 1 forehead). Participants wore the electrodes for a total of four hours each session. Sleep latency, total sleep time, time spent in each stage of sleep, and stage of sleep upon awakening were assessed.
Actigraphs -SleepWatch-L model actigraphs were issued to each participant (Ambulatory Monitoring, Inc., Ardsley, NY). The actigraph resembles a wristwatch and was worn in a similar manner. A small accelerometer systematically recorded the individual's movement over time, both while awake and asleep, allowing for the objective identification of sleep/wake patterns (Brown, Smolensky, D'Alonzo, & Redman, 1990) . Each participant wore an actigraph for three days prior to each test day. Actigraphy was used to confirm activity log results.
Activity Log -Participants recorded their sleep intervals as they occurred for three days prior to each experimental session using a modified version of the form developed by the Air Force Research Laboratory (Cantrell & Hartman, 1967) . This form allowed us to assess the number of hours slept each night for the three days prior to each session. Subjective rating scales were also provided to periodically register sleepiness ratings. Procedures A training session was conducted the week prior to data collection. During training, participants completed 6 trials of the ANAM battery to assure asymptotic performance on each test. Training on the other tests required only a single trial, and was conducted on the morning of the first experimental session. At the conclusion of the training session, participants were given actigraphs and activity logs for the first test week.
For each experimental session, participants arrived at 1030 hrs and completed one ANAM training test trial to become re-familiarized with the tests. Participants were also introduced to the remaining tests at that time. Lunch was served after these familiarization trials. EEG electrodes were then installed and data recording begun. Prior to sleep, participants completed their first testing trial at 1200 hrs (baseline). Drug administration occurred at 1300 hrs and participants slept from 1300 to 1630 hrs. Participants were awakened at 1630 hrs and were told to remain in bed until a proctor 7 could help them into their chairs at the computer workstations. Testing began once everyone was seated (1630 hrs, which is 3.5-hr post-dose). Testing was performed again at 1700 hrs, and was repeated hourly through 2000 hrs. Participants were given half hour breaks each hour. At the conclusion of the first test day, participants were given actigraphs and activity logs for the next test week. Participants returned the following week for the second experimental session.
Statistical Analyses Drug Comparisons
Before any statistical analyses were performed, the data was baseline-adjusted to counter any potential week-to-week differences in an individual's responses. This was accomplished for each outcome measure (except Williams word memory and PSG responses, which did not have baselines) by subtracting a subject's baseline response from each of his post-drug responses. These "deltas" became the data for statistical analysis.
For each continuous, normally distributed, outcome measure, a repeated measures analysis of variance was performed (using the delta data) to test for significant drug main effects and/or drug by time interaction. A Huyhn-Feldt adjustment was made for variables that failed Mauchly's Test of Sphericity. When significant drug effects were detected, post-hoc simple effects tests (Winer, pg. 174) were used to compare the zaleplon change from baseline with the placebo change from baseline at each post-drug time point, separately. For discrete outcome measures, and measures where nonnormality was suspected, Wilcoxon signed-rank tests were used to compare the drug and placebo conditions for differences in the change from baseline at each of the post-dose trials, separately. Finally, for polysomnographic variables, Student's one-tailed paired t-tests were used to compare the effects of zaleplon with placebo.
Sleep Inertia
Only data from the first four trials (baseline, 3.5-hr post-dose, 4-hr post-dose, 5-hr post-dose) of the placebo condition were examined to determine sleep inertia effects. The analysis was restricted to the placebo data to insure that any changes seen would be due to a simple sleep inertia effect, and would not be compounded by a possible zaleplon carryover. A repeated measures ANOVA with one withinsubjects factor (time) was performed on each dependent measure. When a significant effect was observed, post-hoc comparisons between baseline and each of the post-awakening time periods were performed using Student's t-tests.
Power Analysis
The number of subjects for this study was calculated from an a priori power analysis of the planned post-hoc comparisons between the two drug conditions. We determined that, when testing at the 0.05 alpha level, a sample of 12 participants would provide an 88% chance (power) of detecting a standardized effect size (ES) =1.0 when comparing the change under zaleplon with the change under placebo at any given time point.
RESULTS
One of the twelve participants was dropped from the study due to the development of a medical concern unrelated to the study. An additional participant was removed from the polysomnographic analysis due to data loss in for one experimental session. The results will be discussed in two sections The first section details the outcomes of the drug comparisons. The second section examines only the placebo data for sleep inertia effects. Any mention of statistical significance refers to an alpha level 8 2^1eplon vs. Placebo Comparisons For all variables that were recorded over the hourly trials, descriptive statistics are shown in Appendix A, along with the analysis results. The first column contains the actual baseline (pre drug) means as a point of reference. The remaining columns contain the mean changes from baseline, which were the means being compared in the statistical analyses. Descriptive statistics and results for the polysomnography variables are shown in Appendix B. Results for any other variables are summarized in the text. Graphs are presented for all variables showing significant effects. In the graphs, for ease of interpretation, the means, rather than the mean deltas are shown. For variables where non-parametric tests were performed, means were used in both the tables and the graphs to provide trend information even though the analyses were based on the ranked data. Note that the 3.5-hr post-dose trial is the trial performed immediately upon awakening, and contains data from 3.5-4 hrs post-dose. Similarly, the other post-dose trials began at the time indicated post-dose and had a duration of25-40 min.
Sleep and Activity
Based on data collected with the activity logs, there was no difference between the average sleep attained preceding the zaleplon and placebo sessions. Overall, participants averaged 6.8 hours of sleep the night prior to an experimental session. The mean sleep start time was 23:54. Polysomnography See Appendix B for details of the analyses performed on the polysomnographic variables. Mean total sleep time (TST) was significantly longer under zaleplon compared to placebo (182 min vs. 163 min). Consequently, sleep efficiency was also significantly higher during the zaleplon session (87% vs. 76%). Total slow wave sleep (TSWS = stage 3 + stage 4 sleep) was significantly greater for the zaleplon condition (54.0 vs. 37.4 min). Split into Stages 3 and 4, separately, we observed a significant gain in stage 3 sleep under zaleplon (60% increase over placebo), and a borderlinesignificant (p<.10) gain in stage 4 sleep under zaleplon (37% increase over placebo). To aid with interpretation of the analysis results for TST and TSWS, individual subject responses are shown in Figures 1 and 2 . Note that four subjects (those with the lowest placebo TST) experienced large increases in TST under the zaleplon condition (ranging from 21% to 74% improvement), whereas the six subjects whose placebo TST's were already high, experienced moderate to little improvement under zaleplon (in fact, 3 did not accomplish as much sleep under zaleplon). Thus we observed, for zaleplon, that the TST range and standard deviation are greatly reduced when compared to placebo. Similar results were seen for TSWS: Five of the six subjects with the lowest placebo TSWS showed very large increases under zaleplon ranging from 86% to 148% improvement (the sixth showed only slight improvement), whereas the four subjects whose placebo TSWS's were already high experienced little improvement under zaleplon (two did not accomplish as much TSWS imder zaleplon). Finally, note that every subject showed improvement under zaleplon in at least one of the two measures (TST or TSWS).
The results for the remaining polysomnographic measures were less remarkable. The times spent in stages 1,2, and REM were nearly identical for the zaleplon and placebo sessions. There was no significant difference found for sleep latency. Code Substitution Test-Learning-A significant drug by trial interaction was detected for MRTC, and a significant drug main effect was detected for throughput. Under zaleplon, MRTC significantly' decreased fi-om baseline at both the 4-hr (t(10)=2.67, P=.023) and 7-hr (t(10)=2.95, P=.015) post-dose trial when compared to placebo (see Fig 3) . Under zaleplon, throughput significantly increased from baseline values at both the 4-hr (t(10)=2.83, P=.018) and 7-hr (t(10)=2.80, P=.019) post-dose trials when compared to placebo (see Fig 4) .
Code Substitution Test-Immediate-No significant drug effects were seen for any of the five outcome measures.
Code Substitution Test-Delayed-No significant drug effects were seen for any of the five outcome measures. Math Processing Test-A significant drug by trial interaction was detected for accuracy. However, from the post-hoc tests, no significant difference was found between placebo and zaleplon at any specific trial. No statistical differences were found for any of the other four outcome measures.
Mean RT to Correct Responses
Logical Reasoning Test-No significant drug effects were seen for any of the five outcome measures.
Match to Sample Test-Significant drug main effect differences were detected for MRTC and throughput. Under zaleplon, MRTC significantly decreased from baseline at both the 5-hr (t(10)-2.97, P=.014) and 7-hr (t(10)=3.70, P=.004) post-dose trial when compared to placebo (see Fig  5) . Under zaleplon, throughput significantly increased from baseline values at the 4-hr (t(10)=3.84, P-.003), 5-hr (t(10)=2.69, P=.023) and 7-hr (t(10)=4.64, P<.001) post-dose trials when compared to placebo (see Fig 6) . Psychomotor Vigilance Test-No significant drug effects were seen for any of the three outcome measures.
Williams Word Memory Test-There was no within-session baseline for this test. Consequently, evaluations were made by comparing the percent correct between placebo and zaleplon at each time point, separately. Given the discrete nature of the data a Wilcoxon Signed Rank Test was utilized. Word recall was significantly higher under zaleplon than under placebo (z=2.22, p=.026) at the 7-hr post-dose trial (see Fig 7) . Sleep-Aid Symptoms Questionnaire-To prepare for significance testing, difference scores indicating the change fi-om baseline to each of the post-awakening trials were calculated. A Wilcoxon signedrank test was then performed comparing the drug conditions. No significant differences were found between the drug conditions for any of the 17 variables analyzed. (See Appendix C for symptom summary values) Following awakening in the second experimental session, participants were asked to identify which drug they received. Forty five percent of the participants (5 out of 11) guessed the dose accurately.
Sleep Inertia Results
As indicated in "methods", only the first four placebo trials were analyzed for sleep inertia effects. The ANOVA results are summarized in Appendix D for all variables analyzed. The means that were tested are the same as were previously shown in Appendix B. Figures are provided for all variables where significant sleep inertia was foimd.
Code Substitution Test-Leaming-Significant trial main effects were detected for MRTC and throughput. MRTC significantly increased at the 3.5-hr (t(10)=3.22, p=.009) post-dose trial when compared to baseline (see Fig 8) . Throughput significantly decreased at the 3.5-hr (t(10)=3.86, p=.003) and 4-hr (t(10)=2.26, p=.048) post-dose trials (see Fig 9) .
Mean RT to Correct Responses * sig. change from baseline Code Substitution Test-Immediate-A significant trial main effect was detected for throughput (see Fig 10) . Throughput significantly decreased at the 3.5-hr (t(10)=2.25, p=.048) post-dose trial when compared to baseline. 
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Code Substitution Test-Delayed-No significant trial main effects were detected for any of the four outcome measures.
Math Processing Test-No significant trial main effects were detected for any of the four outcome measures.
Logical Reasoning Test-Significant trial main effects were detected for MRTC and throughput. Post-hoc comparisons indicated increased MRTC (t(10)=3.14, p=.010) and decreased throughput (t(10)=3.31, p=.008) at the 3.5-hr post-dose trial, when compared to baseline (Fig.s 11 & 12,  respectively) . Nlatch to Sample Test-No significant trial main effects were detected for any of the four outcome measures.
Simple Reaction Time Test-A significant trial main effect was detected for MRT. Post-hoc comparisons indicated increased MRT at the 3.5-hr (t(10)=3.72., p=.004) post-hoc trial when compared to baseline (Fig 13) .
MeanRT Figure 13 Simple Reaction Time sig. change from baseline Psychomotor Vigilance Test-A significant trial main effect was detected for MRRT and lapses. No post-hoc comparisons were significant for MRRT (Fig. 14) . Post-hoc comparisons indicated a decrease in lapses at the 4-hr (z=2.06, p=.039) post-dose trial, when compared to baseline (Fig 15) . It is important to remember that the results from this study come from a group of normally entrained mdividiwls who were attempting to sleep during a period when they would normally be awake. The sleep initiation start time was also a time where the propensity to remain asleep is low relative to nighttime levels in unrested individuals (Akerstedt, A. & Gillberg, M., 1981) . Activity log data indicated that participants received what they would consider a normal nights sleep, not quite 7 hrs, prior to the experimental sessions. Thus, while not optimally rested, participants should have been relatively well-rested. This presents somewhat of a worst-case scenario for sleeping (i.e., a period where the drive for sleep should be greatly reduced relative to nighttime levels). In sum, we have sleep being attempted during a moderately fatiguing portion of the day by moderately well-rested individuals. Participants were able to sleep for a substantial duration, 2.72 hrs, under placebo. Thus It IS quite a robust result that zaleplon significantly extended sleep duration (3.03 hrs) in this situation.
MeanRRT
As noted in the results section, four participants responded very positively to zaleplon, five neutrally, and one negatively, in terms of sleep duration. Differences at the individual level could be attributable to a number of phenomena including sleep histoiy or general stress level. Also worth noting is that the six participants unaided by zaleplon all slept around 180 minutes or greater under placebo. The potential benefits of zaleplon for accomplishing sleep three or more hours after ingestion are probably greatly reduced given its short half-life. The reduced range and standard deviation in TST under zaleplon indicate that the drug was stabilizing sleep duration across the group by removing the shorter sleep periods (i.e., the four shortest sleep periods occurred in the placebo group).
Overall, zaleplon improves both the duration and quality of sleep (i.e., amount of slow wave sleep) for the group. Upon examining the data at the individual participant level we observed a considerable improvement in either TST or TSWS, without a decrement in the other, in 7 out of 10 cases. In two cases under zaleplon (participant 71 & 74), we saw a decrease in either TST or TSWS with an increase in the other relative to placebo, hi one case there was a considerable increase in both TST and TSWS (participant 81). T)q)ically then (8 out of 10), participants were aided in their sleep by accomplishing more or better sleep.
There was no drug condition difference observed for sleep latency. Both groups fell asleep quickly (<14 mm). Given this short placebo sleep latency, it is unlikely significant levels of zaleplon were in the participants system since the digestion time of the Sonata® capsule within a gel-cap should be approximately that duration or longer. This is in agreement with Mean Sleep Latency Test results from Richardson, Carskadon, Orav & Dement (1982) where they found participants to have a mean latency to sleep onset of approximately 12-min at 1330hrs. It must be remembered that sleep in this study was accomplished in a light and sound attenuating private room that was slightly cool (70° F). Participants were completely prone, resting upon a comfortable bed with a desired level of sheets and blankets. In other words, the sleep in this study was accomplished under ideal conditions; a situation which may or may not be present in an operational setting. Furthermore participants in this study were precluded from performing any other activities besides sleeping or reading in bed. This forced restriction of activity may well be a principal reason for the accomplishment of the great quantity of sleep observed under the placebo condition.
No deleterious performance effects, cognition, memory, balance or muscular, were observed under zaleplon, when compared to the placebo condition. To the contrary, cognitive performance, as measured by our battery of tests, was significantly improved in several cases for the zaleplon group relative to placebo. Keep in mind that both groups acquired a good deal of sleep. It must be remarked as well that these improved performances occurred at times of day when performance is expected to be at its peak regardless of daytime napping. This improvement in performance was not overwhelming. There were a total of 36 cognitive and memory performance measures taken every trial. We observed improvement in a total of six variables at differing times following awakening. To attempt to determine if there was some facet of sleep that led to improved performance in this study, we examined the relationship between TST and TSWS and some performance variables which exhibited the greatest improvement under zaleplon relative to placebo (e.g., matching to sample throughput). No correlation between performance and either TSWS or TST, using either difference scores or group means, was observed. Thus, there is no clear explanation for the possibly beneficial results of zaleplon Participants were unable to accurately determine whether they had received zaleplon or placebo. Additionally, no significant differences were observed for any of the symptom data. Nor were there any anecdotal reports of discomfort or unease following awakening from zaleplon-induced sleep. Thus participants awakened from a restful sleep not knowing whether they had received a sleep aid or not. This bodes well for post-awakening performance and supports zaleplon use in situations where only short periods are available for sleep.
This research shows zaleplon to be efficacious at promoting sleep in normal individuals during the day. It also shows that zaleplon increased the amount of slow wave sleep. However, as mentioned earlier, these results were observed in an environment ideal for sleep. Further research should investigate the robustness of the hypnotic efficacy of zaleplon by requiring individuals to sleep in less-ideal environments. Li a study designed specifically to examine the sleep promoting effects of zaleplon in a non-conducive sleeping environment. Stone (2001) found zaleplon to reduce the time to persistent sleep over placebo.
Li summary, zaleplon allowed participants to accomplish a greater amount of sleep and to sleep 'more deeply' than under placebo. Furthermore, performance was not adversely impacted following a 3.5 hour daytime sleep under zaleplon. On the contrary, there was the suggestion of improved cognitive performance in several instances. Thus zaleplon has shown significant benefits for individuals attempting to accomplish uninterrupted sleep during a non-optimal rest period.
Sleep Inertia Four ANAM tests out of the seven had measures that showed a performance decrement at the 3.5hr test block. Three of the affected tests occurred within the first 3-minutes after awakening. The fourth affected test. Logical Reasoning, took place from 9 to 12 minutes following awakening. One measure from one test was negatively affected at the 4-hr test block. However, one measure from another test was significantly improved at the 4-hr test block. Thus it appears that there is substantial evidence for sleep inertia occurring up to 12-min following awakening but not thereafter. Half of the participants were awakened from Stage n sleep. The remainder were in REM (n=3). Stage IV(n=l), or very recently self-awakened (n=l).
CONCLUSIONS AND RECOMMENDATIONS
Zaleplon demonstrated significant benefits for individuals attempting to accomplish uninterrupted sleep during a non-optimal rest period. Zaleplon was capable of providing significant sleep enhancement during the day in relatively well-rested individuals. With normal use, zaleplon does not have a deleterious effect upon performance. Indeed performance may be enhanced following a normal awakening from sleep induced by zaleplon. Table   Variable Means SD (diff) t(9df) P 
